about
A Perspective of Immunotherapy for Prostate CancerAdoptive immunotherapy against ovarian cancerChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsMetabolic communication in tumors: a new layer of immunoregulation for immune evasionRecent advances in T-cell engineering for use in immunotherapyReengineering chimeric antigen receptor T cells for targeted therapy of autoimmune diseaseSwitch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells.Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits.Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse modelA new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Immunotherapy and tumor microenvironmentMethods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Engineering of synthetic gene circuits for (re-)balancing physiological processes in chronic diseases.Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelCurrent status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma.Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model.Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Acute myeloid leukaemia.Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.Chimeric antigen receptor T-cell therapies for multiple myeloma.Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.New Chimeric Antigen Receptor Design for Solid Tumors.The Plasma Membrane as a Reservoir, Protective Shield, and Light-Triggered Launch Pad for Peptide Therapeutics.PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.The development of CAR design for tumor CAR-T cell therapy.Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential.EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma.
P2860
Q26741277-12A94835-ADB9-4F56-B6FE-517191936F6CQ26748905-91DFDF59-3446-49E4-8340-95844F3F755AQ26753082-D4F79BEE-F70C-4929-88E7-D834A1BF8E75Q26765256-93A6256A-C829-49ED-8A76-A0E951A1A904Q28080312-DA548C72-78E8-4165-9AED-3C2EDD7D5999Q28276800-054A26CE-B884-4F73-B3E3-F13E14835D40Q36551673-C8F244B4-E87F-476B-8305-43208841FBEAQ36922254-9FD91DCE-E86D-4B08-96FF-C27EFFA0A6B3Q37126699-CECF67C4-FAF5-4B79-AF2C-1801D557A784Q37376269-E57B9C9F-3EED-497A-A1A0-5E280B0D8956Q37555940-696CACB3-E089-4972-9470-1CCD49C5EFF4Q38610306-18B39BFE-6A71-4B28-9DEC-F89DAEC780A3Q38658670-89EB9D4A-63E0-424B-940E-A99C05AD851FQ38694036-ECAFAABD-2C8C-4D9D-95C8-812344BA732FQ38786626-7CDF2DC4-7E50-4F89-8C8B-0F9BB68BC2AEQ38876131-D64C434F-E6D1-4DB5-81EF-B59B73E1F611Q39003162-5A80AC2C-706E-41CF-B2DD-A0DDD93EF1A9Q39037477-738081D8-0079-4F00-9757-782D0785D5CEQ39237421-87BEB404-C80E-4B81-BBD6-B4C56F3D0EE8Q39249589-93E9784A-CB23-4A36-A646-5D3AD1BF9768Q39280002-9241A584-468E-4304-94C2-E7E9C1A96955Q40256333-A2D67024-343C-4305-8C28-B25B29464367Q40616678-C489DEA4-DFC7-4D4C-BD65-1A6CBA3C6B20Q41664346-4CC1EF11-6667-4D37-9563-1D91C65BF281Q42040539-F70E5EB2-D9E1-4519-AA4A-8CD55A3DB40AQ45872592-3DA3F04D-344A-404A-9742-414107063304Q45943585-DA694C9E-C67D-4EE7-B700-4C442C935F33Q47193084-332F1E31-A57D-4261-97E1-B3A9C7D187FDQ47432401-3AE0212F-21F3-4B86-A91E-DB95A7CB53A5Q47570358-343257A7-723F-4E81-AE82-A0878DAB5562Q47776210-3827B26A-3632-4E39-9939-0D827AA73CEFQ49401353-E4E779C2-CB24-4EC8-A933-3C2B91F34753Q49711158-620D4A88-3980-4D6F-BEA1-4562A4E24D97Q50276830-AE658861-67FA-41B1-924B-8D05DFF53BC7Q50534706-630DB1BE-CB8E-4A23-BE5D-FE41FB8D0A47Q52641562-F0FBFAD3-B8FA-4E83-A0DC-61123FA150E5Q52646462-07B34CC8-4D59-4B7C-A330-19E53C13460DQ55251612-F3F8C656-5E1A-4AAA-96D5-C24DD8CF4B12Q55387110-E4F113E0-5A29-46A2-9627-A1885D28475EQ55689740-8F8CF3A5-7404-4EDC-9991-C0F38FBC8F62
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Engineering CAR-T cells: Design concepts.
@en
type
label
Engineering CAR-T cells: Design concepts.
@en
prefLabel
Engineering CAR-T cells: Design concepts.
@en
P2860
P356
P1433
P1476
Engineering CAR-T cells: Design concepts.
@en
P2093
Shivani Srivastava
Stanley R Riddell
P2860
P304
P356
10.1016/J.IT.2015.06.004
P577
2015-07-11T00:00:00Z